Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 9, 2017. The document serves as a transaction notification regarding share allocations for Independent Non-Executive Directors for the service period of October 1, 2016, to December 31, 2016.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price | Volume |
|---|---|---|---|
| 2017-02-08 | Ordinary Shares (GBP) | £15.55 | 5,827.665 (Aggregated) |
| 2017-02-08 | American Depositary Shares (USD) | $39.47 | 1,966.705 (Aggregated) |
Material Changes
The filing reports initial notifications of acquisitions of notional shares and ADSs by seven directors. There are no material changes to the company's financial position or operations reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a routine disclosure of director share allocations.
Investor Verification Points
- Verify the total number of Ordinary Shares and ADSs allocated to directors for the Q4 2016 service period.
- Confirm the transaction price of £15.55 per Ordinary Share and $39.47 per ADS reflects the market value on the transaction date (February 8, 2017).
- Note that these are "notional" acquisitions under share allocation arrangements, not open market purchases by the directors.